norfloxacin has been researched along with Cronobacter Infections in 20 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In cirrhotic rats with ascites: (a) pentoxifylline as well as norfloxacin reduced intestinal bacterial overgrowth and bacterial translocation and prevented spontaneous bacterial peritonitis; (b) pentoxifylline, but not norfloxacin, reduced oxidative stress in cecal mucosal." | 7.78 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. ( Acevedo, J; Brusasco, C; Corradi, F; Fernández, J; Fernández-Varo, G; Gines, P; Mosbah, IB; Navasa, M; Pelosi, P; Ramirez, MJ; Rocco, PR; Seva-Pereira, T; Silva, A; Vila, J, 2012) |
| "We carried out quantitative culturing of stools from 31 hospitalized alcoholic patients with cirrhosis and ascites, before treatment with 400 mg of norfloxacin per day, weekly for the first month, and then every 2 weeks thereafter for 15 to 229 days (median, 54 days)." | 7.69 | Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. ( Campillo, B; Dupeyron, C; Fouet, P; Leluan, G; Mangeney, N; Sedrati, L, 1994) |
| "In cirrhotic rats with ascites: (a) pentoxifylline as well as norfloxacin reduced intestinal bacterial overgrowth and bacterial translocation and prevented spontaneous bacterial peritonitis; (b) pentoxifylline, but not norfloxacin, reduced oxidative stress in cecal mucosal." | 3.78 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. ( Acevedo, J; Brusasco, C; Corradi, F; Fernández, J; Fernández-Varo, G; Gines, P; Mosbah, IB; Navasa, M; Pelosi, P; Ramirez, MJ; Rocco, PR; Seva-Pereira, T; Silva, A; Vila, J, 2012) |
| "We carried out quantitative culturing of stools from 31 hospitalized alcoholic patients with cirrhosis and ascites, before treatment with 400 mg of norfloxacin per day, weekly for the first month, and then every 2 weeks thereafter for 15 to 229 days (median, 54 days)." | 3.69 | Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. ( Campillo, B; Dupeyron, C; Fouet, P; Leluan, G; Mangeney, N; Sedrati, L, 1994) |
| "Twenty-four patients with complicated urinary tract infections were treated with norfloxacin for three months." | 3.67 | Norfloxacin treatment in complicated urinary tract infection. ( Boerema, JB; van Saene, HK, 1986) |
| "Norfloxacin was as effective and safe as trimethoprim-sulfamethoxazole without emergence of resistant bacteria associated with trimethoprim-sulfamethoxazole." | 2.66 | Efficacy of norfloxacin in urinary tract infection biological effects on vaginal and fecal flora. ( Schaeffer, AJ; Sisney, GA, 1985) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| "Pefloxacin was given as the single drug (except in one case) to twenty-seven patients with a variety of infections (bone and/or joint: 8; respiratory tract: 6; urinary tract: 5; bacteremia: 4; meninges: 3; other: 1)." | 1.27 | [Pefloxacin: clinical experience]. ( Bertrand, A; Janbon, F; Jonquet, O; Jourdan, J; Santoni, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (50.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pérez, A | 1 |
| Canle, D | 1 |
| Latasa, C | 1 |
| Poza, M | 1 |
| Beceiro, A | 1 |
| Tomás, Mdel M | 1 |
| Fernández, A | 1 |
| Mallo, S | 1 |
| Pérez, S | 1 |
| Molina, F | 1 |
| Villanueva, R | 1 |
| Lasa, I | 1 |
| Bou, G | 1 |
| Quiroga, MP | 1 |
| Andres, P | 1 |
| Petroni, A | 1 |
| Soler Bistué, AJ | 1 |
| Guerriero, L | 1 |
| Vargas, LJ | 1 |
| Zorreguieta, A | 1 |
| Tokumoto, M | 1 |
| Quiroga, C | 1 |
| Tolmasky, ME | 1 |
| Galas, M | 1 |
| Centrón, D | 1 |
| Barguigua, A | 1 |
| Ouair, H | 1 |
| El Otmani, F | 1 |
| Saile, R | 1 |
| El Mdaghri, N | 1 |
| El Azhari, M | 1 |
| Timinouni, M | 1 |
| Bert, F | 1 |
| Leflon-Guibout, V | 1 |
| Le Grand, J | 1 |
| Bourdon, N | 1 |
| Nicolas-Chanoine, MH | 1 |
| Corradi, F | 1 |
| Brusasco, C | 1 |
| Fernández, J | 1 |
| Vila, J | 1 |
| Ramirez, MJ | 1 |
| Seva-Pereira, T | 1 |
| Fernández-Varo, G | 1 |
| Mosbah, IB | 1 |
| Acevedo, J | 1 |
| Silva, A | 1 |
| Rocco, PR | 1 |
| Pelosi, P | 1 |
| Gines, P | 1 |
| Navasa, M | 1 |
| Fukuyama, M | 1 |
| Kawakami, K | 1 |
| Suda, O | 1 |
| Imagawa, Y | 1 |
| Runyon, BA | 1 |
| Borzio, M | 1 |
| Young, S | 1 |
| Squier, SU | 1 |
| Guarner, C | 1 |
| Runyon, MA | 1 |
| Dupeyron, C | 1 |
| Mangeney, N | 1 |
| Sedrati, L | 1 |
| Campillo, B | 1 |
| Fouet, P | 1 |
| Leluan, G | 1 |
| Chollet, R | 1 |
| Bollet, C | 1 |
| Chevalier, J | 1 |
| Malléa, M | 1 |
| Pagès, JM | 1 |
| Davin-Regli, A | 1 |
| Grangé, JD | 1 |
| Amiot, X | 1 |
| Fujimaki, K | 1 |
| Fujii, T | 1 |
| Aoyama, H | 1 |
| Sato, K | 1 |
| Inoue, Y | 1 |
| Inoue, M | 1 |
| Mitsuhashi, S | 1 |
| Ewer, TC | 1 |
| Bailey, RR | 1 |
| Gilchrist, NL | 1 |
| Aitken, JM | 1 |
| Sainsbury, R | 1 |
| Michéa-Hamzehpour, M | 1 |
| Pechère, JC | 1 |
| Marchou, B | 1 |
| Auckenthaler, R | 1 |
| Aoki, T | 1 |
| Shimizu, N | 1 |
| Tomizawa, I | 1 |
| Takizawa, Y | 1 |
| Matsubara, Y | 1 |
| Seo, T | 1 |
| Sagara, H | 1 |
| Tagawa, K | 1 |
| Masuda, G | 1 |
| Negishi, M | 1 |
| Schaeffer, AJ | 1 |
| Sisney, GA | 1 |
| Esko, E | 1 |
| Renkonen, OV | 1 |
| Boerema, JB | 1 |
| van Saene, HK | 1 |
| Isaacs, RD | 1 |
| Ellis-Pegler, RB | 1 |
| Fernandes, PB | 1 |
| Chu, DT | 1 |
| Bower, RR | 1 |
| Jarvis, KP | 1 |
| Ramer, NR | 1 |
| Shipkowitz, N | 1 |
| Bertrand, A | 1 |
| Janbon, F | 1 |
| Jourdan, J | 1 |
| Jonquet, O | 1 |
| Santoni, A | 1 |
2 reviews available for norfloxacin and Cronobacter Infections
| Article | Year |
|---|---|
[Emergence of vancomycin-dependent enterococci following glycopeptide therapy: case report and review].
Topics: Bacterial Proteins; Bacteriuria; Carbon-Oxygen Ligases; Cecal Diseases; Ceftriaxone; Citrobacter fre | 2009 |
[Prophylaxis of infectious complications by selective digestive bacterial decontamination in patients with cirrhosis].
Topics: Anti-Bacterial Agents; Ascitic Fluid; Bacterial Infections; Decontamination; Digestive System Diseas | 1992 |
3 trials available for norfloxacin and Cronobacter Infections
| Article | Year |
|---|---|
Comparative study of norfloxacin and trimethoprim for the treatment of elderly patients with urinary tract infection.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Bacteriuria; Clinical Trials as Topic; Enterobacteria | 1988 |
[Comparison of clinical efficacy of norfloxacin (NFLX) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Norfloxacin Research Group Enteritis].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Dysentery, | 1987 |
Efficacy of norfloxacin in urinary tract infection biological effects on vaginal and fecal flora.
Topics: Adult; Anal Canal; Anti-Infective Agents, Urinary; Bacteriuria; Drug Combinations; Drug Resistance, | 1985 |
15 other studies available for norfloxacin and Cronobacter Infections
| Article | Year |
|---|---|
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
Topics: Bacterial Proteins; Base Sequence; beta-Lactamases; Carrier Proteins; Cloning, Molecular; DNA, Bacte | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross I | 2007 |
Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in community setting in Casablanca.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carrier State; Ciproflo | 2015 |
Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Translocatio | 2012 |
[In vitro antibacterial activity of balofloxacin (BLFX) against isolates from patients with bacterial enteritis].
Topics: Anti-Infective Agents; Drug Resistance, Microbial; Enteritis; Enterobacteriaceae Infections; Escheri | 1995 |
Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis.
Topics: Administration, Oral; Animals; Carbon Tetrachloride Poisoning; Enterobacteriaceae; Enterobacteriacea | 1995 |
Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis.
Topics: Ascites; Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Feces; Human | 1994 |
mar Operon involved in multidrug resistance of Enterobacter aerogenes.
Topics: Amino Acid Sequence; Anti-Infective Agents; DNA, Bacterial; Drug Resistance, Microbial; Drug Resista | 2002 |
Quinolone resistance in clinical isolates of Serratia marcescens.
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; DNA Topoisomerases, Type II; Drug Resistan | 1989 |
Combination therapy: a way to limit emergence of resistance?
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftriaxone; Drug Resistance, Microbial; Drug Therapy, Com | 1986 |
Comparative in vitro activity of norfloxacin and seven other antimicrobial agents against clinical isolates from urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Cefaclor; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; | 1985 |
Norfloxacin treatment in complicated urinary tract infection.
Topics: Adolescent; Adult; Aged; Bacteriuria; Child; Enterobacteriaceae Infections; Female; Humans; Male; Mi | 1986 |
Successful treatment of Morganella morganii meningitis with pefloxacin mesylate.
Topics: Aged; Anti-Infective Agents; Enterobacteriaceae Infections; Female; Humans; Meningitis; Microbial Se | 1987 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |
[Pefloxacin: clinical experience].
Topics: Acinetobacter Infections; Adult; Aged; Bacterial Infections; Enterobacteriaceae Infections; Enteroco | 1985 |